Overview of NRG1 Fusions

Opinion
Video

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, define NRG1 fusions and outline their incidence and effect on prognosis.

Educational support for this activity provided by Merus.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
1 expert in this video
1 expert in this video
1 expert in this video
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Related Content
Higher social vulnerability index was independently associated with lower odds of meeting at least one quality criterion in treatment for PDAC.

Disparities in Treatment/Survival Outcomes Observed in Metastatic PDAC

Roman Fabbricatore
April 15th 2025
Article

Higher social vulnerability index was independently associated with lower odds of meeting at least one quality criterion in treatment for PDAC.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Mitigating NALIRIFOX-Related Diarrhea May Extend Survival in Metastatic PDAC

Mitigating NALIRIFOX-Related Diarrhea May Extend Survival in Metastatic PDAC

Ashley Chan
April 12th 2025
Article

Post hoc analysis of the NAPOLI 3 trial suggests that proactively managing NALIRIFOX-induced diarrhea could allow patients with PDAC to remain on treatment longer.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

Tanios S. Bekaii-Saab, MD, FACP
November 25th 2024
Podcast

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic neuroendocrine tumors.

FDA Approves Cabozantinib in Pancreatic/Extra-Pancreatic Neuroendocrine Tumors

Roman Fabbricatore;Ariana Pelosci
March 26th 2025
Article

Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic and extra-pancreatic neuroendocrine tumors.

OSE2101 Plus FOLFIRI Meets OS End Point in Advanced PDAC

OSE2101 Plus FOLFIRI Meets OS End Point in Advanced PDAC

Tim Cortese
March 12th 2025
Article

The OSE2101 cancer vaccine plus FOLFIRI chemotherapy demonstrated positive survival data with minimal toxicities in the phase 2 TEDOPaM trial.